Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: Results from the American college of surgeons oncology group Z1031 trial (alliance)

Journal of Clinical Oncology

Volumn 35, Issue 10, 2017, Pages 1061-1069

  Ellis, Matthew J ^a   Suman, Vera J ^e   Hoog, Jeremy ^f   Goncalves, Rodrigo ^f   Sanati, Souzan ^f   Creighton, Chad J ^a   DeSchryver, Katherine ^f   Crouch, Erika ^f   Brink, Amy ^f   Watson, Mark ^f   Luo, Jingqin ^f   Tao, Yu ^f   Barnes, Michael ^h   Dowsett, Mitchell ^j   Budd, G Thomas ^k   Winer, Eric ^m   Silverman, Paula ^l   Esserman, Laura ⁱ   Carey, Lisa ⁿ   Ma, Cynthia X ^f   Unzeitig, Gary ^c   Pluard, Timothy ^g   Whitworth, Pat ^p   Babiera, Gildy ^b   Guenther, J Michael ^q   Dayao, Zoneddy ^r   Ota, David ^o   Leitch, Marilyn ^d   Olson, John A ^s   Allred, D Craig ^f   Hunt, Kelly ^b   more..

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Doctors Hospital of Laredo   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g St Lukes Hospital   (United States)

^h Digital Pathology   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j ROYAL MARSDEN HOSPITAL   (United Kingdom)

^k LERNER RESEARCH INSTITUTE   (United States)

^l CASE WESTERN RESERVE UNIVERSITY   (United States)

^m DANA FARBER CANCER INSTITUTE   (United States)

ⁿ UNIVERSITY OF NORTH CAROLINA   (United States)

^o DUKE UNIVERSITY   (United States)

^p Nashville Breast Center   (United States)

^q St Elizabeth Medical Center   (United States)

^r UNIVERSITY OF NEW MEXICO   (United States)

^s UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GEMCITABINE; KI 67 ANTIGEN; LETROZOLE; PACLITAXEL; TRASTUZUMAB; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; NITRILE; PROGESTERONE RECEPTOR; TRANSCRIPTOME; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; DRUG EFFICACY; FEMALE; HUMAN; KI67 BASED PREOPERATIVE ENDOCRINE PROGNOSTIC INDEX; LONG TERM CARE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT RESPONSE; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; GENETICS; METASTASIS; MITOSIS INDEX; NEOADJUVANT THERAPY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TUMOR RECURRENCE;

AGED; ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL DECISION-MAKING; FEMALE; FOLLOW-UP STUDIES; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; MITOTIC INDEX; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NITRILES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TRANSCRIPTOME; TRIAZOLES;

EID: 85016622416     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.69.4406     Document Type: Article

References (21)

1. Goncalves R, Ma C, Luo J, et al: Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer. Nat Rev Clin Oncol 9: 223-229, 2012
2. Cortazar P, Zhang L, Untch M, et al: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 384:164-172, 2014
3. DeMichele A, Yee D, Berry DA, et al: The neoadjuvant model is still the future for drug development in breast cancer. Clin Cancer Res 21: 2911-2915, 2015
4. Eiermann W, Paepke S, Appfelstaedt J, et al: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized doubleblind multicenter study. Ann Oncol 12:1527-1532, 2001
5. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
6. Ellis MJ, Coop A, Singh B, et al: Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63:6523-6531, 2003
7. Ellis MJ, Tao Y, Luo J, et al: Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100:1380-1388, 2008
8. Ellis MJ, Suman VJ, Hoog J, et al: Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 29: 2342-2349, 2011
9. Olson JA Jr, Budd GT, Carey LA, et al: Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: Results from a multicenter phase II trial. J Am Coll Surg 208:906-914, 2009; discussion 915-916
10. Dowsett M, Smith IE, Ebbs SR, et al: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167-170, 2007
11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
12. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc Ser A 135: 185-207, 1972
13. Whitfield ML, Sherlock G, Saldanha AJ, et al: Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13:1977-2000, 2002
14. Creighton CJ: Multiple oncogenic pathway signatures show coordinate expression patterns in human prostate tumors. PLoS One 3:e1816, 2008
15. Dowsett M, Nielsen TO, A'Hern R, et al: Assessment of Ki67 in breast cancer: Recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103:1656-1664, 2011
16. Fisher B, Jeong JH, Bryant J, et al: Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364:858-868, 2004
17. Loibl S, Jackisch C, Lederer B, et al: Outcome after neoadjuvant chemotherapy in young breast cancer patients: A pooled analysis of individual patient data from eight prospectively randomized controlled trials. Breast Cancer Res Treat 152: 377-387, 2015
18. Huober J, von Minckwitz G, Denkert C, et al: Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: Overall results from the GeparTrio study. Breast Cancer Res Treat 124:133-140, 2010
19. Albain KS, Barlow WE, Ravdin PM, et al: Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: A phase 3, open-label, randomised controlled trial. Lancet 374:2055-2063, 2009
20. Ellis MJ, Ding L, Shen D, et al: Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486:353-360, 2012
21. Ma CX, Reinert T, Chmielewska I, et al: Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer 15:261-275, 2015